PhaseV

🎉 Happy International Clinical Trials Day! To mark the occasion, we're launching a new mini-series — short videos, every few weeks, sharing the PhaseV perspective on what's shaping clinical development. 👉 First up: a clip from BioIT World, where Neta Shanwetter Levit, PhaseV's Clinical & Data Ops Lead interviews our CEO, Raviv Pryluk! #ClinicalTrialsDay #ClinicalDevelopment #AIinClinicalTrials #PhaseV

⏰ One week away — and spots are filling up! TECH WEEK by a16z is coming to Boston, and PhaseV is hosting 𝘛𝘳𝘪𝘢𝘭𝘴 𝘪𝘯 𝘔𝘰𝘵𝘪𝘰𝘯 on May 27th at 10:00 AM — One Broadway, Cambridge, MA. If you haven't registered yet, now's the time 👇 https://lnkd.in/eM-ckX4N Raviv Pryluk Yael Gozin Aman Bhandari Chris Decker Hamza Sheikh #BOSTechWeek #ClinicalDevelopment #AIinClinicalTrials #Pharma #Tech

It's conference season for the PhaseV team! 🎉 We're presenting at #BioITWorld, #ScopeX, and #NESS2026 over the coming two weeks — come find us if you're attending, we'd love to connect! 👋 Raviv Pryluk Hamza Sheikh Adam S. Brown, PhD

My Colleague, Elad Walach said it well "Great technology earns the right to be deployed. It doesn't deploy itself." He was talking about health systems. But in clinical development, the same truth holds. A failed trial doesn't just slow a program, it can end one. And yet, the conversation about AI adoption in pharma still tends to place the burden on one side: either technology companies need to build better tools or processes, or sponsors need to become more innovative. In reality, meaningful adoption requires both. What should be done? On the tech side: - Earn trust the right way; publish your evidence, go through the scientific review process, don't ask sponsors to take your word for it. - Be honest about failures, not just wins; a company that only shares success stories is selling software; one that explains where things broke, what was learned, and how the approach evolved is acting like a long-term partner. - Show up as a change agent, not a critic; the goal is not to dismiss existing workflows, but to help organizations transition from where they are today toward operating models better suited for AI-enabled clinical development. On the pharma side: - Evaluate AI with the same scientific rigor applied to biomarkers, endpoints, or statistical methodologies, not based on familiarity or who happened to present it. - Understand that AI adoption isn't procurement; AI integration into clinical development requires evolved workflows and operational processes and refined decision points. That’s not friction; it’s a natural part of implementing new technology in a highly regulated and scientifically rigorous environment - Find and empower your internal champions. Elad is right that these individuals often determine whether innovation gains traction, and this dynamic is just as true in clinical development as it is in health systems. The optimism is warranted. The science is there. But innovation doesn't win by being right, it wins when both sides show up and evolve together.

Only two weeks until TECH WEEK by a16z in Boston and PhaseV's event 𝘛𝘳𝘪𝘢𝘭𝘴 𝘪𝘯 𝘔𝘰𝘵𝘪𝘰𝘯! 📅 May 27th | 10:00 AM 📍 One Broadway, Fl 5, Cambridge, MA 👉 Sign up here: https://lnkd.in/eM-ckX4N Yael Gozin Aman Bhandari Chris Decker Raviv Pryluk

The PhaseV Team is looking forward to connecting at Fierce Biotech in Boston in the next couple of days! 🔹 Raviv Pryluk, PhaseV's CEO will be talking today at 11.55am "𝘍𝘳𝘰𝘮 𝘗𝘳𝘰𝘵𝘰𝘤𝘰𝘭 𝘵𝘰 𝘦𝘹𝘦𝘤𝘶𝘵𝘪𝘰𝘯: 𝘕𝘢𝘷𝘪𝘨𝘢𝘵𝘪𝘯𝘨 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘊𝘰𝘮𝘱𝘭𝘦𝘹𝘪𝘵𝘺 𝘸𝘪𝘵𝘩 𝘦𝘯𝘥-𝘵𝘰-𝘦𝘯𝘥 𝘈𝘐" 🔹 Reach out to info@phasevtrials.com to connect with Carles Monterrubio, PhD, our Director of BD, or leave a message below 👇 #FierceBiotech #ClinicalTrials #DrugDevelopment #AI

💫 Starting the week with a new post from Oshri Machluf, Tzviel Frostig and the PhaseV team! 👉 𝘕𝘰𝘪𝘴𝘺 𝘌𝘏𝘙 𝘥𝘢𝘵𝘢 𝘪𝘴 𝘢 𝘧𝘢𝘮𝘪𝘭𝘪𝘢𝘳 𝘤𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦 𝘪𝘯 𝘳𝘦𝘢𝘭-𝘸𝘰𝘳𝘭𝘥 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 — 𝘶𝘯𝘪𝘵 𝘦𝘳𝘳𝘰𝘳𝘴, 𝘵𝘺𝘱𝘰𝘴, 𝘢𝘯𝘥 𝘴𝘱𝘢𝘳𝘴𝘦 𝘷𝘪𝘴𝘪𝘵 𝘳𝘦𝘤𝘰𝘳𝘥𝘴 𝘤𝘢𝘯 𝘲𝘶𝘪𝘦𝘵𝘭𝘺 𝘶𝘯𝘥𝘦𝘳𝘮𝘪𝘯𝘦 𝘦𝘷𝘦𝘯 𝘸𝘦𝘭𝘭-𝘥𝘦𝘴𝘪𝘨𝘯𝘦𝘥 𝘢𝘯𝘢𝘭𝘺𝘴𝘦𝘴. In a recent observational study on weight-loss interventions, we used a 𝗛𝗶𝗱𝗱𝗲𝗻 𝗠𝗮𝗿𝗸𝗼𝘃 𝗠𝗼𝗱𝗲𝗹 𝘁𝗼 𝗿𝗲𝗰𝗼𝘃𝗲𝗿 𝗰𝗼𝗵𝗲𝗿𝗲𝗻𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝘄𝗲𝗶𝗴𝗵𝘁 𝘁𝗿𝗮𝗷𝗲𝗰𝘁𝗼𝗿𝗶𝗲𝘀 from messy, error-prone measurements. The technical approach is sound. But the broader takeaway is about team synergy: the best models come from 𝘀𝘁𝗮𝘁𝗶𝘀𝘁𝗶𝗰𝗶𝗮𝗻𝘀, 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻𝘀, 𝗮𝗻𝗱 𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝘀 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝘁𝗼 𝗱𝗿𝗶𝘃𝗲 𝗿𝗲𝗮𝗹 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵. 🔵 Full post linked below: https://lnkd.in/e492daTG #MarkovModel #WeightLossStudy #Teamwork #ErroneousMeasurement

𝗘𝘃𝗲𝗿𝘆 𝗰𝗵𝗮𝗻𝗴𝗲, 𝘀𝘂𝗰𝗵 𝗮𝘀 𝗮 𝗰𝗵𝗮𝗻𝗴𝗲 𝘁𝗼 𝗮 𝗽𝗿𝗶𝗺𝗮𝗿𝘆 𝗲𝗻𝗱𝗽𝗼𝗶𝗻𝘁, 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗶𝗽𝗽𝗹𝗲 𝗶𝗻𝘀𝘁𝗮𝗻𝘁𝗹𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝘁𝗼𝗰𝗼𝗹, 𝗦𝗔𝗣, 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗽𝗹𝗮𝗻, 𝗯𝘂𝗱𝗴𝗲𝘁 𝗽𝗿𝗼𝗷𝗲𝗰𝘁𝗶𝗼𝗻𝘀, 𝗼𝗿 𝗧𝗟𝗙𝘀. Today, it doesn't. 𝘛𝘦𝘢𝘮𝘴 𝘴𝘱𝘦𝘯𝘥 𝘸𝘦𝘦𝘬𝘴 𝘳𝘦𝘤𝘰𝘯𝘤𝘪𝘭𝘪𝘯𝘨 𝘤𝘩𝘢𝘯𝘨𝘦𝘴 𝘢𝘤𝘳𝘰𝘴𝘴 𝘥𝘰𝘤𝘶𝘮𝘦𝘯𝘵𝘴 𝘵𝘩𝘢𝘵 𝘸𝘦𝘳𝘦 𝘯𝘦𝘷𝘦𝘳 𝘤𝘰𝘯𝘯𝘦𝘤𝘵𝘦𝘥 𝘵𝘰 𝘣𝘦𝘨𝘪𝘯 𝘸𝘪𝘵𝘩. 𝘉𝘺 𝘵𝘩𝘦 𝘵𝘪𝘮𝘦 𝘢 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘨𝘦𝘵𝘴 𝘮𝘢𝘥𝘦, 𝘵𝘩𝘦 𝘵𝘳𝘢𝘥𝘦𝘰𝘧𝘧𝘴 𝘢𝘳𝘦 𝘢𝘭𝘳𝘦𝘢𝘥𝘺 𝘰𝘣𝘴𝘤𝘶𝘳𝘦𝘥. This is the problem PhaseV has spent years building toward and we have now redefined how clinical trials are designed and executed. 𝗧𝗼𝗱𝗮𝘆, 𝘄𝗲'𝗿𝗲 𝗿𝗲𝗹𝗲𝗮𝘀𝗶𝗻𝗴 𝗔𝗜 𝗖𝗼𝗻𝗱𝘂𝗰𝘁𝗼𝗿 The result: 🔹 𝟭𝟬𝘅 𝗳𝗮𝘀𝘁𝗲𝗿 trial design and iteration 🔹 𝗠𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟱𝘅 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗺𝗲𝗻𝘁 𝗶𝗻 𝗰𝗼𝘀𝘁 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 🔹 𝗙𝗲𝘄𝗲𝗿 𝗽𝗿𝗼𝘁𝗼𝗰𝗼𝗹 𝗮𝗺𝗲𝗻𝗱𝗺𝗲𝗻𝘁𝘀 through better upfront decisions 👉 Watch PhaseV AI Conductor demo

Last week, the FDA sent reminder letters to 2,200+ clinical trial sponsors about unreported results — and roughly 30% of trials that should be reporting haven't submitted anything. 𝘛𝘩𝘪𝘴 𝘪𝘴𝘯'𝘵 𝘫𝘶𝘴𝘵 𝘢 𝘵𝘳𝘢𝘯𝘴𝘱𝘢𝘳𝘦𝘯𝘤𝘺 𝘪𝘴𝘴𝘶𝘦. 𝘞𝘩𝘦𝘯 𝘧𝘢𝘪𝘭𝘦𝘥 𝘵𝘳𝘪𝘢𝘭𝘴 𝘨𝘰 𝘶𝘯𝘳𝘦𝘱𝘰𝘳𝘵𝘦𝘥, 𝘸𝘦 𝘭𝘰𝘴𝘦 𝘵𝘩𝘦 𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘵𝘰 𝘶𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥 𝘸𝘩𝘺 𝘱𝘳𝘰𝘨𝘳𝘢𝘮𝘴 𝘧𝘢𝘪𝘭. 𝗪𝗮𝘀 𝗶𝘁 𝘁𝗵𝗲 𝗱𝗿𝘂𝗴? 𝗧𝗵𝗲 𝘁𝗿𝗶𝗮𝗹 𝗱𝗲𝘀𝗶𝗴𝗻? 𝗧𝗵𝗲 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗲𝗻𝗿𝗼𝗹𝗹𝗲𝗱? Without that detail, failures become invisible — and we end up overestimating success rates, underestimating risk, and making worse decisions. At PhaseV, we're building tools to work around this data gap — but the problem shouldn't exist in the first place. The data is out there. It's just not being shared. Read our latest on why missing trial results are a modeling problem, not just an ethics one. 👇 #ClinicalDevelopment #UnreportedResults #FailedTrials #AIML #MLinPharma https://lnkd.in/eh5bhG8w

𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘪𝘴 𝘩𝘢𝘱𝘱𝘦𝘯𝘪𝘯𝘨 𝘪𝘯 𝘴𝘪𝘭𝘰𝘴. 𝘋𝘢𝘵𝘢, 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴, 𝘢𝘯𝘥 𝘴𝘵𝘢𝘬𝘦𝘩𝘰𝘭𝘥𝘦𝘳𝘴 𝘢𝘤𝘳𝘰𝘴𝘴 𝘧𝘶𝘯𝘤𝘵𝘪𝘰𝘯𝘴 𝘳𝘦𝘮𝘢𝘪𝘯 𝘭𝘢𝘳𝘨𝘦𝘭𝘺 𝘥𝘪𝘴𝘤𝘰𝘯𝘯𝘦𝘤𝘵𝘦𝘥 𝘧𝘳𝘰𝘮 𝘰𝘯𝘦 𝘢𝘯𝘰𝘵𝘩𝘦𝘳. This fragmentation is costing biopharma billions and delaying patient access to effective therapies. PhaseV solves this with a causal AI-powered connected intelligence layer and has delivered measurable impact across 𝟴𝟬+ 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀 including up to 𝟱𝟬% 𝗿𝗲𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗶𝗻 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗰𝗼𝘀𝘁𝘀, 𝟰𝟬% 𝗳𝗮𝘀𝘁𝗲𝗿 𝘁𝗿𝗶𝗮𝗹 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲𝘀, 𝗮𝗻𝗱 𝗺𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟯𝟬% 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝗣𝗼𝗦. Curious to learn more? Find us at the following conferences: 🔷At BIO-IT World Conference & Expo (May 19–21, Boston), Raviv Pryluk, CEO & Co-Founder, will present in the “𝘈𝘐 𝘧𝘰𝘳 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺, 𝘗𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘔𝘦𝘥𝘪𝘤𝘪𝘯𝘦 & 𝘏𝘦𝘢𝘭𝘵𝘩” track on Wednesday, May 20 at 12:10 PM. 🔷 At SCOPE-X (May 18–19, Boston), Hamza Sheikh, VP, Business & Corporate Development, will present in the “𝘈𝘐 𝘚𝘵𝘳𝘢𝘵𝘦𝘨𝘺 𝘢𝘯𝘥 𝘉𝘶𝘴𝘪𝘯𝘦𝘴𝘴 𝘝𝘢𝘭𝘶𝘦 𝘪𝘯 𝘊𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵” track on Tuesday, May 19 at 1:25 PM. Our partnerships team, including Carles Monterrubio, PhD , Yael Hadad, and Miri Idan Malik, will be on the ground for meetings.